Jodi Stephenson, MD
Psychiatry · Providence, RINPI 1437163136
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 85.5% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $369 and has fallen 56.9% since, to $159 in 2025.
Across 56 payments — averaging $19.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$928
- Johnson & Johnson$83
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$22
- E.r. Squibb & Sons, L.L.C.$22
- Otsuka America Pharmaceutical, Inc.$17
- Neurocrine Biosciences, Inc.$14
What the payments were for
- Food & beverage$1,086100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 49 | $928 |
| Johnson & Johnson | 3 | $83 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Neurocrine Biosciences, Inc. | 1 | $14 |
How this compares
$1,086 in reported general payments places this provider in the 80th percentile of 209 psychiatry providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Vilazodone Hcl | 39 | $3,451 |
| Methylphenidate ErMethylphenidate Hcl | 24 | $2,203 |
| Memantine Hcl | 58 | $1,641 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 37 | $1,547 |
| Perphenazine | 16 | $1,504 |
| Clomipramine Hcl | 21 | $1,439 |
| Lamotrigine | 98 | $1,269 |
| Fluoxetine Hcl | 97 | $1,091 |
| Naltrexone Hcl | 21 | $1,025 |
| Clonazepam | 143 | $983 |
| Buspirone Hcl | 70 | $966 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 18 | $926 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 73 | $885 |
| Armodafinil | 30 | $867 |
| Gabapentin | 76 | $860 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Providence
- James GreerProvidence$780K
- Linda CarpenterProvidence$37K
- Steven RasmussenProvidence$6K
- Kazi SalahuddinProvidence$4K
- Marygene Santa TeresaProvidence$3K
- Kathryn Erickson-RidoutProvidence$2K
- Laura MayerProvidence$2K
- Lawrence PriceProvidence$2K
- Katharine PhillipsProvidence$1K
- Benjamin GreenbergProvidence$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.